ISRCTN43452247 https://doi.org/10.1186/ISRCTN43452247

Mechanisms of transiently impaired renal function during liver transplantation

Submission date	Recruitment status	[_] Prospectively registered
21/06/2008	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
12/09/2008	Completed	[_] Results
Last Edited	**Condition category**	[_] Individual participant data
12/09/2008	Urological and Genital Diseases	[_] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Eduardo Schiffer

Contact details
Hopitaux Universitaires de Geneve
24 Micheli-du-Crest
Geneva
Switzerland
1211

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
CER 03-159; SHR 369-08

Study information

Scientific Title

Renal function during the perioperative period of liver transplantation

Study objectives
Hyperreninism is the major mediator of transient and acute anuria during the anhepatic phase of liver transplantation.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Ethics Committee of the Geneva University Hospitals (Commission central d'éthique de la recherche sur l'être humain des HUG). Date of approval: 24/01/2004 (ref: CER 03-159)

Study design
Observational, prospective, cross-sectional study

Primary study design
Observational

Secondary study design
Cross-section survey

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet

Health condition(s) or problem(s) studied
Liver transplantation

Interventions
Observational study: Blood sampling for biologic assessment of renal function at the time of inclusion in the waiting list, at the time of anaesthesia induction on the day of liver transplantation, during the anhepatic phase, 24 hours later and finally at 6 months.

Intervention Type
Other

Phase
Not Specified

Primary outcome measure
Renal function: plasma renin activity, assessed in all blood samples (see Interventions).

Secondary outcome measures

The following were assessed in all blood samples (see Interventions):
1. Cystatin C
2. Natraemia

Overall study start date
01/08/2004

Completion date
01/01/2008

Eligibility

Key inclusion criteria
1. Both males and females
2. Age 17-70 years
3. Patients scheduled for liver transplantation

Participant type(s)
Patient

Age group
Adult

Sex
Both

Target number of participants
30

Key exclusion criteria
Incapacity to comprehend the study protocol

Date of first enrolment
01/08/2004

Date of final enrolment
01/01/2008

Locations

Countries of recruitment
Switzerland

Study participating centre

Hopitaux Universitaires de Geneve
Geneva
Switzerland
1211

Sponsor information

Organisation
Geneva University Hospitals (Hôpitaux Universitaires de Genève) (Switzerland)

Sponsor details
24 Micheli du Crest
Geneva
Switzerland
1211

Sponsor type
Hospital/treatment centre

Website
http://www.hug-ge.ch

ROR
https://ror.org/01m1pv723

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
Geneva University Hospitals (Hôpitaux Universitaires de Genève) (Switzerland)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration